SCHEMBL16652006

SCHEMBL16652006

Cn1c(=O)[nH]cc(Br)c1=O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.36
ADORA2B P29275 2/20 0.36
ADORA3 P0DMS8 1/20 0.34
ADORA1 P30542 1/20 0.34
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.32
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
CSNK2A2 P19784 1/20 0.32
CSNK2B P67870 1/20 0.32
CSNK2A1 P68400 1/20 0.32
CRBN Q96SW2 1/20 0.31
APAF1 O14727 1/20 0.31
CASP6 P55212 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221825 0.74 SLC9A1 (0.41) ADORA2AADORA2BADORA3ADORA1ALDH1A1
5-Bromouracil SCHEMBL28330235 0.73 ATAD2 (0.36) ALDH1A1LMNAMAPTTSHRPMP22
SCHEMBL11480635 0.73 ADORA2A (0.36) ADORA2AADORA2BADORA3ADORA1ALDH1A1
SCHEMBL28179392 0.73 FEN1 (0.31)
SCHEMBL9685966 0.73 ALDH1A1 (0.37) ADORA2AADORA2BADORA3ADORA1ALDH1A1
SCHEMBL8167544 0.73 TDP1 (0.38) ALDH1A1
SCHEMBL2078821 0.73 ADORA2A (0.36) ADORA2AADORA2BADORA3ADORA1ALDH1A1
SCHEMBL25979874 0.73 ADORA2A (0.36) ADORA2AADORA2BADORA3ADORA1ALDH1A1
SCHEMBL27423099 0.72 ADORA2A (0.33) ADORA2AADORA2BADORA3ADORA1ALDH1A1
SCHEMBL11723298 0.72 ALDH1A1 (0.35) ADORA2BALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119662655-A Application of RNA molecule and composition thereof in tumor immunotherapy 武汉厚先生物医药有限公司 2025-03-21 CN disclosed
WO-2023220428-A1 COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-11-16 WO disclosed
WO-2023220440-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-11-16 WO disclosed
CN-116916936-A Compositions and methods for delivering RNA 再生技术有限责任公司 2023-10-20 CN disclosed
CN-116425682-A Pyrimidine-1 (2H) -oxo compound and preparation method and application thereof 深圳信立泰药业股份有限公司 2023-07-14 CN disclosed
EP-3708566-B1 NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2023-02-08 EP disclosed
CN-115515559-A Rectal delivery of messenger RNA 翻译生物公司 2022-12-23 CN disclosed
CN-107428744-B Novel heterocyclic compounds and their use in medicine and cosmetics 盖尔德马研究及发展公司 2021-09-24 CN disclosed
EP-3708566-A1 NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS Galderma Research & Development (FR) 2020-09-16 EP disclosed
EP-3237403-B1 NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2020-05-06 EP disclosed
US-10246422-B2 Heterocyclic compounds and use thereof in medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-04-02 US disclosed
EP-2875006-B1 ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2018-12-26 EP disclosed
US-20180050992-A1 NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2018-02-22 US disclosed
US-9428465-B2 Acid ceramidase inhibitors and their use as medicaments FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) 2016-08-30 US disclosed
US-20150111892-A1 ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111892-A1 ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS ASAH1, ASAH2, ACER2 ADORA2A 3419/4885ADORA2B 2076/4885ADORA3 2330/4885
US-20180050992-A1 NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS MC1R, CALCRL, BDKRB2 ADORA2A 377/4885ADORA2B 346/4885ADORA3 243/4885
US-10246422-B2 Heterocyclic compounds and use thereof in medicine and in cosmetics MC1R, BDKRB2, CCKBR ADORA2A 381/4885ADORA2B 326/4885ADORA3 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.